The first published evidence of the clinical activity of BET inhibitors refers to a phase I clinical trial with OTX015, in which promising antitumor activity was seen in both acute leukemia and other hematological malignancies (Patrice Herait, AACR Annual Meeting, San Diego, LA, USA; Oral communication, April, 2014). The gene discussed is DNER; the disease is hematologic disorder.